semaglutide cardiovascular outcomes news 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Cardiovascular Outcomes, Safety, and Tolerability

GLP-1 Medications and Weight Loss: Helping Patients Navigate Beyond the Trends

You should tell your doctor before starting any of these medications if you: Have problems with your kidneys Have had gastrointestinal disease (particularly pancreatitis) Are pregnant, planning a pregnancy or breastfeeding Have had allergic reactions to any medications GLP-1 analogues and Driving GLP-1 analogues should not affect your ability to drive, cycle or use machinery or tools as long as your blood glucose levels are stable

Compounded retatrutide is not an FDA-approved finished product

Moreover, the senescence phenotype depends on specific pathologies or tissues, making the identification of selective markers essential for the development of new senolytic drug families